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Abstract
The diversion, misuse, and non-medically supervised use of buprenorphine and buprenorphine/
naloxone by opioid users are reviewed. Buprenorphine and buprenorphine/naloxone are used
globally as opioid analgesics and in the treatment of opioid dependency. Diversion of
buprenorphine and buprenorphine/naloxone represents a complex medical and social issue, and
has been widely documented in various geographical regions throughout the world.
We first discuss the clinical properties of buprenorphine and its abuse potential. Second, we
discuss its diversion and illicit use on an international level, as well as motivations for those
activities. Third, we examine the medical risks and benefits of buprenorphine’s non-medically
supervised use and misuse. These risks and benefits include the effect of buprenorphine’s use on
HIV risk and the risk of its concomitant use with other medications and drugs of abuse. Finally,
we discuss the implications of diversion, misuse, and non-medically supervised use (including
potential measures to address issues of diversion); and potential areas for further research.
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INTRODUCTION
Opioid Dependence: Extent of the Problem
Opioid abuse and dependence are major medical and social concerns throughout the world,
contributing to excessive morbidity, mortality, disability, and economic costs [1, 2]. The
United Nations Office on Drugs and Crime notes that opiates, particularly heroin, are the
main problem drugs at a global level, with an estimated 15.6 million opioid abusers globally,
including approximately 11.1 million heroin abusers [3]. The WHO also estimates that there
are approximately 12.6 million injection drug users (IDUs) in the world [4], with injection
drug use reported in over 150 countries and territories globally [5]. While the prevalence of
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injection drug use may be low in any given general population, IDUs represent a major point
of entry for HIV into a population; according to UNAIDS, injection drug use accounts for
up to 80% of HIV infections in Eastern Europe and Central Asia [6].
In addition to the risk of HIV infection and transmission, other harms associated with
injection drug use present additional medical challenges. Unsafe injection practices have
contributed to an international epidemic of Hepatitis C virus, with an estimated 120 million
people infected worldwide [7]. Abscesses, endocarditis, and soft tissue infections are
prominent concerns for the health of IDUs [8–10]. Finally, regular use of opioids, regardless
of the route of administration, results in lasting biological and physiological changes in the
brain, including disruptions in inhibitions, motivation, and decision-making processes [11].
Opioid replacement therapy with methadone or buprenorphine is a clinically effective
treatment for opioid dependence. Methadone was first used to treat opioid dependence in the
1960’s [12]. It is a synthetic full mu-receptor agonist that is usually administered to patients
orally on a daily basis for opioid replacement [13]. Buprenorphine, which is described in
greater detail below, is a partial mu-agonist that is administered sublingually to patients
undergoing opioid substitution therapy [13]. Studies examining the effectiveness of opioid
substitution treatment have found that it results in superior retention rates (in comparison to
abstinence only treatment) [14], reduces the amount of illict and nonprescribed opioids used
by patients [12, 14–16], decreases criminal activity [14, 17], and helps to reduce the
transmission of HIV among drug users and the occurrence of high-risk injection practices
[14, 17–19].
While the ultimate goal of substance abuse treatment is abstinence, opioid addiction is a
chronic, relapsing medical condition. In this article, we take a harm reduction approach to
analyze the use of buprenorphine and buprenorphine/naloxone by opioid users.
Buprenorphine - Course of Action, Safety, and Clinical Efficacy
Buprenorphine is a relatively long-acting partial mu agonist and full kappa antagonist
administered sublingually in opioid replacement therapy [13, 20, 21]. Buprenorphine is
commonly sold alone (Subutex®) or in a coformulation with naloxone (Suboxone®) to
prevent parenteral abuse [13, 22–25]. As a partial agonist, buprenorphine exhibits a ceiling
effect at high doses. This means that there is a plateau observed for buprenorphine’s opioid
agonist effects, such as sedation and respiratory depression, even at high doses. In
experimental settings, doses up to 70 times the recommended analgesic dose were well
tolerated in non-dependent males who had previous experience with opioids [20].
Buprenorphine was first used at low doses as an analgesic for post-operative and cancer
patients in the late 1970s [26, 27]. Shortly thereafter, reports of buprenorphine misuse—
marketed at the time as Tamgesic®—began to surface in New Zealand [28] and reports of
injection misuse arose in Europe [29]. A recent report from the World Health Organization
Expert Committee on Drug Dependence noted that, while diversion is currently occurring
and does pose a public health concern, the risk-to-benefit ratio for the continued use of
buprenorphine is favorable [30].
High-dose buprenorphine—available in 0.4mg, 2.0mg, and 8.0mg doses—was introduced in
1980 for the treatment of opioid dependency [31–33]. Buprenorphine is a well-suited
medication for opioid replacement therapy due to its activity as a partial opioid agonist.
Buprenorphine can be substituted for full agonists, such as heroin or morphine, to prevent
withdrawal but it can also be slowly withdrawn without large discomfort, as is often
experienced with methadone [34].
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Numerous trials and reviews have established buprenorphine as an effective treatment for
opioid dependence. Buprenorphine is safe and effective for use in acute detoxification,
stabilization, and long-term maintenance of individuals with opioid dependence. In a
randomized controlled trial of buprenorphine, Johnson and colleagues found that
buprenorphine was effective in maintaining patients in treatment and reducing the
consumption of illicit opioids [35]. Additional studies have shown that office-based
treatment (OBT) with buprenorphine is effective and safe for the treatment of opioid
dependency [36, 37]. Office-based therapy provides additional benefits, including
minimization of contact with other drug users and of the stigma associated with drug
dependence [21, 38]. As a result of buprenorphine and buprenorphine/naloxone’s safety
profiles, the U.S. National Institute on Drug Abuse has identified the medication as a first-
line treatment for opioid dependence [39]. The WHO also added buprenorphine as a
complementary medication to the 14th edition of The Model of List of Essential Medicines
[4].
Buprenorphine is intended for sublingual administration. Due to extensive first-pass liver
metabolism, oral dosing of buprenorphine results in low bioavailability and is not feasible.
With sublingual administration, the medication achieves sufficient bioavailability after being
dissolved under the tongue, usually within 5–7 minutes of administration. Buprenorphine/
naloxone is also intended for sublingual dosing, and while the sublingual bioavailability of
buprenorphine is relatively high (ca. 35–55%), that of naloxone is low (ca. 10%); this
property allows the combination buprenorphine/naloxone product to deliver the effects of
the opioid without those of the antagonist, when used as directed [24, 40, 41]. If
buprenorphine/naloxone is injected, however, the bioavailability of naloxone is high; in such
an instance, the naloxone component is intended to both precipitate withdrawal and block
the euphoric/analgesic effects of buprenorphine in opioid-dependent individuals [25].
However, at the current 4:1 buprenorphine/naloxone coformulation ratio, the naloxone
component does not significantly reduce the effects of buprenorphine when the combination
product is injected by individuals who are not dependent on opioids [42]. Thus,
buprenorphine/naloxone is intended to reduce the risk of abuse via injection [22–25].
Although the analgesic properties of buprenorphine and its potential indication for pain
management were documented as early as the 1970’s, new research has examined
buprenorphine’s role in chronic pain management, post-operative pain management, and
non-cancer pain management. In particular, the efficacy and safety of transdermal
buprenorphine has been studied with positive results. Transdermal buprenorphine was
studied with chronic osteoarthritis patients, demonstrating good efficacy and tolerability
[43], and was also studied in a randomized controlled trial for chronic low back pain, where
it was effective at managing pain in patients who had previously received opioids [44]. The
use of sublingual buprenorphine for pain management has also been studied, with the
medication showing a high degree of efficacy, tolerability, and safety in patients with
chronic pain syndrome, even in individuals who suffer from opioid addiction [45]. In a
double-blind comparison of sublingual and transdermal buprenorphine in patients with
osteoarthritis pain, both forms showed similar efficacy, and transdermal buprenorphine
demonstrated better tolerability among patients [46]. Although buprenorphine has not been
extensively used in clinical practice for pain management, current evidence suggests that
buprenorphine may be well-suited for pain management, particularly in high-risk patients,
such as diabetics, the elderly, or individuals with renal failure, due to buprenorphine’s good
safety profile, ceiling effect on respiratory depression, low incidence of adverse events, and
pharmacokinetics that are unaltered by age or renal function [47].
Buprenorphine is currently used in dozens of countries throughout the world for the
treatment opioid dependence and, in some instances, for pain management. Dosing policies,
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access to treatment, levels of patient supervision, and government policies vary widely
among individual countries.
Since 1995, all primary care physicians in France have been able to prescribe buprenorphine
to patients suffering from opioid dependence. Physicians in France are not required to
undergo any specific training to prescribe buprenorphine and do not have any limits on the
number of patients who may receive buprenorphine [48]. In that country, HIV prevalence
and rates of fatal opioid overdose among IDUs have dropped significantly since the
widespread introduction of buprenorphine [31]. By 2006, approximately 95,000 patients
were receiving buprenorphine for the treatment of opioid dependence in France [49].
The United States was the first country to widely use combination buprenorphine/naloxone
(Suboxone®) for office-based treatment (OBT) of opioid dependence. Under provisions of
the US Drug Abuse Treatment Act of 2000 (DATA 2000), any physician can undergo a
training course and subsequently apply for a license to prescribe buprenorphine/naloxone to
individuals with opioid dependence on an out-patient basis [48]. Each physician is initially
limited to 30 patients, but can later apply to prescribe buprenorphine/naloxone to a
maximum of 100 patients [48].
Buprenorphine was approved in Australia in 2000 for detoxification and maintenance of
opioid-dependent patients [50, 51]. Patients commonly receive their dose of buprenorphine
in a pharmacy or community clinic, where the pharmacist or a staff member directly
administers the medication on-site, usually waiting 3–5 minutes before staff inspect the
patient’s oral cavity [52]. Buprenorphine/naloxone (Suboxone®) was approved for the
treatment of opioid dependence in 2005 [51].
Buprenorphine was first introduced in India in 1986 as an analgesic (Tidigesic®), and
reports of buprenorphine ampoule abuse were reported shortly thereafter [53].
Buprenorphine was approved for the treatment of opioid dependence in India in 1999 [54].
In Malaysia, buprenorphine was first licensed for prescription in 2003, and was not highly
regulated. Consequently, reports of abuse quickly emerged and, in 2006, buprenorphine/
naloxone was introduced to replace buprenorphine in the Malaysian market with the aim of
decreasing the practice of buprenorphine injection [55].
Abuse Potential of Buprenorphine
Several studies have examined the reinforcing effects and abuse potential of buprenorphine.
Buprenorphine administration in non-opioid dependent individuals produces the euphoric
effects typically associated with opioids [56, 57]. Subsequent research has demonstrated that
buprenorphine does exhibit positive-reinforcement properties, similar to other opioids [58–
60]. For example, in a study conducted by Comer et al., participants received a dose of
buprenorphine, buprenorphine/naloxone, or placebo and $20, and were subsequently
allowed to choose between a dose or $20 in a choice session; those who received the actual
medication were more likely to self-administer another dose in comparison to those
receiving the placebo [58]. Another evaluation of buprenorphine in detoxified males with
heroin dependence produced significant euphoria in the participants, but the abuse liability
was considered moderate in comparison to morphine [61]. The abuse potential for
buprenorphine is generally considered to be less than that of full opioid agonists [62, 63].
Collectively, these data indicate that there is some cause for concern regarding initiation of
opioid misuse with buprenorphine, although this risk is lower than that of most other
opioids.
In opioid-dependent individuals, sublingual or parenteral administration of buprenorphine
may precipitate withdrawal and/or limit the reinforcing effect of full agonist opioids, due to
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its properties as a high-affinity partial agonist [30, 64–68]. Therefore, due to
buprenorphine’s mixed agonist-antagonist properties, several studies have concluded that
the risk of buprenorphine abuse among opioid-dependent individuals is relatively low [31,
58, 69].
A direct comparison of the prevalence of buprenorphine and buprenorphine/naloxone abuse
is difficult, since each product was introduced into different locations at different times. For
example, in the United States, the monoproduct was never extensively used before the
introduction of the combination product, and heroin remains cheap and highly accessible on
the street. As a result, buprenorphine is not a major drug of abuse in the US. On the
contrary, in many European and Asian countries, buprenorphine monoproduct was available
for years before the introduction of the coformulated product, and limited heroin availability
may have prompted IDUs to make buprenorphine their primary drug, especially in regions
where buprenorphine was not highly regulated. Thus, the overall prevalence of
buprenorphine or buprenorphine/naloxone abuse is not simply a function of the biological
properties of these medications, but rather is dependent on a variety of social, cultural,
political, and economic forces.
BUPRENORPHINE DIVERSION AND ILLICIT USE
Diversion and Illicit Use of Buprenorphine
Buprenorphine abuse by injection was first recorded in the mid-1980s [28, 29]. In the last
two-and-a-half decades, buprenorphine diversion and illicit use have been documented in
countries around the world. In some countries, such as Finland, buprenorphine is the most
widely abused opioid, whereas its abuse in other nations exists to a much lesser extent.
Regardless of the location, various studies, which will be explored further in this section,
have identified motivations for illicit use and abuse. Table 1 displays information from a
selection of relevant studies examining buprenorphine diversion from various geographical
locations. The studies displayed in Table 1 represent articles on buprenorphine diversion that
were published within the last 10 years. The goal of this table is not to be an exhaustive list
of studies; instead it illustrates the range of geographic locations where buprenorphine
diversion has been noted, along with relevant findings to demonstrate the range of diversion
levels in diverse geographical settings.
Since buprenorphine’s widespread introduction in France for the treatment of opioid
dependence in 1995, illicit use and misuse of buprenorphine have been widely documented.
One study reported up to 20% of buprenorphine patients were misusing their prescription
intravenously [31] (see Table 1). Another French study found that 27% of IDUs were
exclusive buprenorphine injectors, with another 37% reporting polydrug use [70]; some of
these IDUs may have purchased their buprenorphine from individuals with a prescription
[71], while others may have obtained buprenorphine by altering or forging prescriptions [63,
72, 73]. Obadia et al. reported similar findings, with 24% of their IDU sample reporting
exclusive buprenorphine use and 34% reporting polydrug use with buprenorphine [74].
While injection of buprenorphine remains the most commonly reported route of
administration for misuse of the medication, sniffing has also been reported in France [75]
and elsewhere [76].
In Finland, buprenorphine, which has been used for pain management since 1997 and was
introduced in 2002 for the treatment of opioid dependence, is the most commonly abused
drug by IDUs and the most commonly abused opioid [77, 78]. A sharp increase in the
misuse of buprenorphine coincided with a notable decrease in 2001 in the availability of
heroin in Finland [77]. Among those entering treatment for opioid dependence, Aalto et al.
found that 29 of 30 patients (97%) reported buprenorphine as their primary drug of abuse
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[77]. Among a larger sample of syringe exchange program (SEP) participants in Finland
(n=176), buprenorphine was the most frequently abused injection drug (73% of
respondents), yet a significant portion of these individuals reported using buprenorphine in a
therapeutic manner, to self-treat withdrawal or addiction [79] (see Table 1). Elsewhere in
Europe, illicit buprenorphine use has been reported in Sweden [80], Scotland [81, 82],
Norway [83], Ireland [84], and Spain [85].
Numerous studies have examined the issue of misuse and non-medically supervised use of
buprenorphine in Australia, where the medication is strictly regulated. Buprenorphine was
introduced in Australia in 2000, followed by the introduction of buprenorphine/naloxone in
2006 in response to concerns of buprenorphine diversion and illicit use [86]. In two separate
studies, about 1/3 of IDUs reported recent buprenorphine injection [87, 88] (see Table 1);
however, buprenorphine was the primary drug of abuse in only about 10% of IDUs [87]. A
significant proportion of primary buprenorphine injectors had a prescription for the
medication [87]. In a cross-sectional study of clients receiving buprenorphine in public
clinics, about one-quarter (26.5%) had ever injected buprenorphine and most patients
reported wanting to take their medication as prescribed [50] (see Table 1). Buprenorphine
diversion by patients receiving supervised dosing at pharmacies has also been reported in
Australia, which often occurs when patients remove the tablet before it is fully dissolved
[89, 90]. In a recent study with 440 patients receiving opioid substitution therapy
(methadone, buprenorphine, or buprenorphine/naloxone), Horyniak and colleagues found
that 18% of their Australian participants ever inhaled buprenorphine or buprenorphine/
naloxone, with smoking being the most common form of inhalation, while rates of
buprenorphine and buprenorphine/naloxone snorting were relatively low. While lifetime
rates of inhalation were relatively high, rates of recent inhalation were low. The authors
postulated that these rates may indicate experimentation and not chronic use, and also
propose that inhalation may represent a harm reduction approach to reduce the use of
injectable opioids [86].
In the United States, buprenorphine was approved for analgesic use (Buprenex®) in 1985 as
a Schedule V Medication. Buprenrophine (Subutex®) and buprenorphine/naloxone
(Suboxone®) were introduced for office-based treatment of opioid dependence in 2002 as
Schedule III Medications [91]. Buprenorphine/naloxone is a first-line option for office-based
treatment, with the buprenorphine monoproduct used occasionally for the induction phase
[92, 93]. The SAMHSA (Substance Abuse Mental Health Services Administration)
Consensus Panel on Buprenorphine recommends that buprenorphine/naloxone be used for
the induction, stabilization, and maintenance of most patients in the United States [94].
Currently, approximately 15,700 physicians can prescribe buprenorphine for the treatment
of opioid dependence, with an estimated 3.5M prescriptions written for buprenorphine or
buprenorphine/naloxone in 2008 [91]. Low levels of abuse have been detected since the
medications’ introduction, with buprenorphine and buprenorphine/naloxone generally
ranked as the least-abused or misused opioid among those studied (examples of other
opioids with higher rates of abuse in the U.S. include heroin, oxycodone, hydrocodone,
methadone, morphine, and fentanyl) [95–99]. Buprenorphine/naloxone diversion has been
limited and illicit buprenorphine/naloxone—which is frequently acquired from individuals
with prescriptions—is commonly used in a therapeutic, non-medically supervised manner
[33, 100, 101] (see Table 1).
In 2006, the Malaysian government replaced buprenorphine, which was introduced in 2001
[102], with buprenorphine/naloxone to address concerns of buprenorphine misuse and
injection [55]. After the transition to buprenorphine/naloxone, there was no reduction in
injection risk behaviors among IDUs, but an increase in their use of benzodiazepines [55]
(see Table 1). The concomitant use of benzodiazepines has been identified elsewhere, and
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has been attributed to an increase in euphoric effects of buprenorphine [53], although further
investigation into the exact motivations for the concomitant use of buprenorphine and
benzodiazepines is warranted. In some areas, benzodiazepines may be available over-the-
counter, which may increase rates of concomitant use with buprenorphine. Despite reported
withdrawal symptoms, IDUs did not decrease their self-administration of buprenorphine/
naloxone [55]. In another Malaysian study, a large majority of buprenorphine IDUs reported
lifetime (ca 100%) or current (ca 63%) heroin use [64] and many buprenorphine/naloxone
injectors had developed methods to avoid the effects of naloxone, which included dividing
the tablets into small pieces or mixing it with heroin or benzodiazepines [64]. Reports of
buprenorphine abuse in India indicate that the use of street-acquired buprenorphine is
common among heroin injectors [103]. Recent studies identified buprenorphine as the
second most commonly injected drug (after heroin) in India, and also raised concern over
the number of new IDUs who initiate injection with buprenorphine [104].
MOTIVATIONS FOR BUPRENORPHINE DIVERSION AND INJECTION
Motivations for Buprenorphine Injection
While the practice of diverting buprenorphine has been established in many regions
throughout the world, few studies have examined the motivating factors for such diversion.
Several publications, which are explored below, have identified price, withdrawal
management, insufficient dosing, a lack of other drugs, and a pursuit of euphoria as possible
motivations.
Price—In some regions, buprenorphine is cheaper than heroin when obtained legitimately
for pharmacotherapy or when illicitly purchased on the streets [87]. In some instances, rising
prices of other injectables may influence a transition to buprenorphine [33, 105, 106] or the
lower price of buprenorphine may appeal to injectors who have limited income [84].
Additionally, the decision to inject buprenorphine may also be influenced by cost, as smaller
doses can be used in comparison to sublingual dosing [64, 107]. Indeed, injection use of
buprenorphine is the most biologically efficient route of administration (in terms of
bioavailability) [108–111], with smaller IV doses required to obtain euphoric effects in
comparison to other routes of administration. Although this efficiency may initially appear
more economical, an individual who injects buprenorphine will quickly develop a level of
tolerance that could ultimately result in greater consumption of buprenorphine.
Depending on the geographic region and the degree of availability of illicit buprenorphine,
the medication may be significantly less expensive than comparable doses of other opioids.
In other cases, heroin may be adulterated or hard to acquire. All of these conditions may
contribute to the acquisition and use of illicit buprenorphine [84, 87, 105, 106, 112].
Euphoria—In any area with accessible buprenorphine, some level of diversion and abuse is
to be expected, as is the case with all opioid medications. In various studies, rates of
euphoria seeking, or using buprenorphine to “get high” range from 10% in some regions of
Australia to 97% in Finland [79, 87] (see Table 1). As illustrated by the “Diversion and
Illicit Use of Buprenorphine” section of this article, buprenorphine abuse rates vary widely
across different geographic regions.
Illict Use as a Response to Sub-Optimal Clincial Dosing or Due to a Lack of
Other Drugs—In some instances, patient misuse of buprenorphine by injection or
inhalation may be indicative of sub-optimal clinical dosing [74, 75, 113]. In such cases,
patients may not be receiving an adequate dose of buprenorphine, may be attempting to
maintain the clinical effects of buprenorphine while using less medication (for instance, due
to financial constraints), or may be diverting some of their medication to others (for
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therapeutic purposes or for misuse) while still attempting to maintain buprenorphine’s
therapeutic effects.
Other Motivations for Buprenorphine Diversion
Studies examining buprenorphine diversion and illicit use have identified additional
motivations for such behavior. In Singapore, for example, Chong et al. note that there is a
false belief among IDUs that intravenous administration of buprenorphine can enhance
erection [107]. In India, where buprenorphine was introduced as an ampoule analgesic in
1986, one study found that buprenorphine users, who constitute about 30% of all IDUs
[104], were less likely to face threats of arrest in comparison to heroin users, that
buprenorphine users believed they were less likely to be harassed by the police if they
possessed buprenorphine rather than heroin, and that buprenorphine users generally only had
minor histories of arrest and incarceration [114] (see Table 1). In another Indian study, an
association was found between intensified police presence and increased injection of
buprenorphine in comparison to the injection of heroin [106]. Collectively, these data
indicate that law enforcement efforts may influence the drug use profiles of a population and
may inadvertently encourage drug-dependent individuals to utilize forms of drugs that
outwardly appear less illegal. Additionally, police enforcement in a particular area may
affect the availability of particular forms of opioids, which could prompt opioid-dependent
individuals to switch to other opioids that have greater local availability.
MEDICAL RISKS AND BENEFITS OF NON-MEDICALLY SUPERVISED
BUPRENORPHINE USE
Medical Benefits of Non-Medically Supervised Buprenorphine Use
While there are public health, medical, social, and legal concerns regarding the misuse and
illicit of buprenorphine, studies have identified various benefits of illicit buprenorphine use.
In many instances, individuals using illicit buprenorphine may be doing so in an attempt to
decrease the illicit use of other opioids, to self-treat opioid dependence, to manage or
mitigate withdrawal symptoms [33, 80, 100, 108], or to attempt to reduce the level of harm
associated with injection drug use [114] (see Table 1). Similarly, studies that examined
differences between buprenorphine and non-buprenorphine IDUs have noted safer injection
practices and lower rates of high-risk HIV activity among buprenorphine injectors [114,
115].
For example, in a recent study in the Republic of Georgia, where buprenorphine is an
unregistered medication, only 13% of IDUs recruited from a needle exchange reported that
buprenorphine was their drug of choice, while 42% reported using buprenorphine to cope
with withdrawal symptoms and 6% used buprenorphine to stop using other drugs [116].
In the United States, a study examining entrants to office-based opioid treatment reported
that a large majority of patients had used non-medically supervised buprenorphine to
prevent cravings and to prevent the onset of withdrawal symptoms [33] (see Table 1). In a
qualitative study in Massachusetts and Vermont, treatment seekers also frequently reported
using illicit buprenorphine and similar results were found, with patients indicating non-
medically supervised buprenorphine use to prevent withdrawal and to self-treat withdrawal
symptoms [100]. A 2009 U.S. study examining the use of illicit buprenorphine among out-
of-treatment injection and non-injection drug users found that a majority of participants used
the medication to reduce opioid withdrawal symptoms and to self-treat opioid addiction,
with more IDUs than non-IDUs reporting buprenorphine use for these purposes. That same
study also noted that about three quarters of IDUs and half of non-IDUs used diverted
Yokell et al. Page 8













buprenorphine because they could not afford to enter formal drug treatment [101] (see Table
1).
Additional data from Hakansson et al. reported in 2007 showed that a majority of surveyed
heroin users (89%) in Sweden reported buprenorphine use in their lifetime, and that among
those illicit users, 87% were using buprenorphine therapeutically, for self-detoxification or
withdrawal treatment. In that same study, sublingual administration of illicit buprenorphine
was most common, consistent with the medication’s intended mode of administration [80].
In Malaysia, Bruce et al. found that injectors were using diverted buprenorphine as a
treatment modality, frequently reporting non-medically supervised buprenorphine use to
avoid heroin or morphine withdrawal. Participants also reported subjective improvements in
quality of life after transitioning to buprenorphine. Buprenorphine use often allowed these
users to obtain and sustain employment, which they were unable to do while injecting heroin
[108].
HIV Risk Behavior and Illicit Buprenorphine
Few studies have examined the associations between non-medically supervised
buprenorphine use and HIV risk behavior. Sullivan et al. found that office-based
buprenorphine treatment in the U.S. was associated with decreased drug-related HIV risk
behavior, including decreased injection drug use and decreased needle sharing among in-
treatment participants [115]. It is possible that non-medically supervised buprenorphine
users experience similar benefits. In India, Kumar et al. noted that illicit buprenorphine
injectors were less likely to share injection equipment and had fewer drug using members in
their social networks [114], which could potentially have a significant impact on injection
drug-related risk of HIV infection. Likewise, in France, individuals who exclusively inject
buprenorphine reported lower rates of needle sharing and polydrug use, while
simultaneously having higher rates of employment in comparison to heroin or cocaine
injectors [31]. Higher rates of employment among exclusive buprenorphine injectors may
indicate that buprenorphine injectors have more stable living situations, possibly due to a
lower severity of addiction, than their heroin- and cocaine-injecting counterparts. What is
not known is whether this is a function of the drug itself or of the type of drug user who uses
buprenorphine by injection.
Medical Risks of Illicit Buprenorphine Use
Despite the therapeutic benefits of non-medically supervised buprenorphine use, concerns
regarding the misuse of diverted buprenorphine, particularly when administered via
injection, should also be considered. Adverse events associated with buprenorphine injection
are similar to those of other injected substances. There have been several reports of
abscesses, soft tissue infections, emboli, acute limb ischaemia, endocarditis, sepsis, and HIV
and Hepatitis C infection associated with injection of buprenorphine [9, 31, 107, 117, 118].
Also, in areas where supervised sublingual dosing of buprenorphine occurs, subsequent
injection of the partially dissolved medication may pose a high risk of microbiological
contamination [87], as microbial flora from a patient’s mouth may be present on the tablet
that will later be injected.
Another concern that arises with the diversion of buprenorphine is the potential that the
medication may be used by individuals experimenting with illicit substances, by individuals
initiating injection administration of drugs, or by individuals who are initiating opioid use
[80, 81]. In Georgia, 11.5% of IDUs reported that buprenorphine was their first drug of
dependence [116], and in France, data suggest that the introduction of buprenorphine may
have contributed to polydrug use among existing injectors [74]. In a recent study in India,
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new initiates of injection were more likely to inject buprenorphine than heroin, which may
be explained by the relatively recent introduction of buprenorphine to that country [104], in
comparison to other opioids, such as heroin, that have been available for many decades.
These data on initiation of injection with buprenorphine in India may be indicative of the
social acceptability of injecting a prescription medication (buprenorphine), as opposed to a
totally illicit drug (heroin), may indicate changes in the general social acceptability of
injection drug use, and/or may reflect the simple fact that buprenorphine was not available
when older IDUs first started injecting opioids. Further research is needed to understand
buprenorphine’s role in the initiation of injection drug use in India. In contrast, in a study of
a national sample of drug users in the United States conducted by some of the authors of this
review, initiation of injection was rare with buprenorphine and co-initiation of heroin use
and buprenorphine was also rare, especially compared to other prescription opioids that were
more commonly co-initiated (methadone pills, hydromorphone, oxycodone) [119].
In comparison to other opioids, the risks associated with buprenorphine diversion are
relatively low. Data indicate that primary buprenorphine injectors do not inject more
frequently than heroin injectors [87] and the euphoric effects of buprenorphine are low in
comparison to full agonists like heroin, oxycontin, hydrocodone, morphine, or methadone
[67, 120, 121]. In comparison to non-prescription opioids (like heroin), buprenorphine
allows users to know the precise dose they are taking and minimizes the risks of other agents
that may be introduced into non-prescription opioids [87].
Collectively these studies examining the risk profiles of buprenorphine users demonstrate
that there is no reason to conclude that buprenorphine users experience any greater risk of
HIV infection or transmission than other IDUs. It is entirely probable that buprenorphine
injectors are at lower risk of HIV infection due to safer injection practices. This may be the
result of less severe withdrawal (in comparison to full agonists) [41] or the long duration of
buprenorphine’s effects [122], which may consequently elicit less desperation, could
provide the user with more time to obtain and prepare the next injection, and may result in a
lower degree of willingness to engage in risky behavior. Further research is needed to assess
relative risks of HIV infection for buprenorphine injectors and other IDUs, and to
differentiate between the effects of buprenorphine on HIV transmission and the
characteristics of buprenorphine injectors that may put them at a decreased risk of HIV
infection.
Concomitant Drug Use and Overdose with Buprenorphine
Concomitant drug use with buprenorphine can present unique medical concerns for the user,
particularly when buprenorphine is combined with benzodiazepines. Overdoses caused
solely by buprenorphine are rare [123], with most overdoses occurring when the medication
is used concomitantly with benzodiazepines or other sedatives [31, 37] (see Table 1).
Despite reports of overdoses involving buprenorphine and benzodiazepines, rates of
overdose have declined by 79% since the introduction of buprenorphine in France [31] and
buprenorphine-related deaths in France, when recorded, are commonly among out-of-
treatment (illicit) buprenorphine users [124].
It is important to note that rates of opioid overdose with buprenorphine are significantly
lower than those associated with methadone [123], due in part to buprenorphine’s ceiling
effect, action as a partial agonist, and limited respiratory depression [20]. A study examining
the relative rates of buprenorphine and methadone deaths in France found that the death rate
attributable to methadone was at least three times greater than that of buprenorphine; the
authors estimated that if all French buprenorphine patients had been treated with methadone
instead of buprenorphine, there would have been approximately 288 deaths from 1994 to
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1998, compared to the 46 deaths that occurred while those patients were in buprenorphine
treatment [125].
DISCUSSION
Is There Sufficient Evidence to Conclude That Buprenorphine Diversion is a Problem?
Numerous studies have documented the presence and, in some instances, the extent of
buprenorphine diversion in varying locations around the world. Although the phenomenon
of buprenorphine diversion is now well established, the literature still lacks a complete
explanation and understanding of the motivations for diversion, therapeutic applications of
diverted buprenorphine, and the sources of illicit buprenorphine. As with other abuseable
medications, in any location where buprenorphine is available, diversion will likely occur.
However, discussions of diversion should be broadened beyond the risks or legal
implications associated with this activity. Strong consideration should also be given to the
medical, social, public health, and economic benefits that arise when opioid-dependent
individuals use buprenorphine in a therapeutic manner to self-treat addiction and withdrawal
symptoms or as a harm reduction approach to manage the risks associated with drug
dependence. Any consideration of diversion should balance the overall benefits—both those
seen in clinical patients as well as those seen in illicit users—with the potential harms.
Do the Benefits of Buprenorphine Outweigh the Risks?
As demonstrated in this review article, buprenorphine has the potential to be a drug of abuse,
and is indeed the major drug of abuse in some geographical areas. Simultaneously, the
clinical efficacy of buprenorphine for the treatment of opioid dependency has been
established, and hundreds of thousands of patients have benefited from its clinical
applications and accessibility. Furthermore, evidence presented in this review indicates that
non-medically supervised buprenorphine is frequently used in a therapeutic manner to self-
treat opioid addiction or withdrawal symptoms in individuals who cannot otherwise access
substance abuse treatment, or who do not want to do so. Illicit use of buprenorphine by
IDUs may also represent a harm reduction approach to reduce the consumption of other
opioids, including the injection use of heroin. Additionally, misuse of buprenorphine—such
as improper dosing, inhalation, or injection—among patients enrolled in buprenorphine
treatment may be a sign of insufficient dosing or dissatisfaction with care. Such episodes of
noncompliance may represent an opportunity for providers to adjust opioid substitution
treatment to better meet the needs of buprenorphine patients.
The relative benefits and risks of buprenorphine should also be compared to those of other
opioids. The abuse liability of buprenorphine and its potential for overdose mortality are less
than that of full opioid agonists [61, 62, 94]. Additionally, buprenorphine precipitates
withdrawal when used by opioid-dependent individuals who have other opioids in their
systems, even if the buprenorphine is not coformulated with naloxone [94].
Finally, buprenorphine’s appeal to individuals with opioid addiction is an important reason
to maintain and expand access to buprenorphine. Participants in several studies have
expressed greater interest in engaging in buprenorphine and continuing buprenorphine
treatment in comparison to methadone, have stated that they would only access
buprenorphine and would not utilize methadone, and have stated a desire to switch from
methadone treatment to buprenorphine treatment if possible [126, 127]. These studies
collectively demonstrate the appeal of buprenorphine to many opioid-dependent individuals
and indicate the need for accessible, community-based buprenorphine treatment.
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Should There be Tighter Control/Monitoring of Buprenorphine?
Tighter controls on buprenorphine will likely increase barriers encountered by opioid-
dependent individuals as they seek treatment, may force “black market” sales of
buprenorphine into more reclusive and dangerous settings, and may result in the sale of
tainted or counterfeit medications to individuals who are seeking illicit buprenorphine for
therapeutic purposes. Thus, any increases in control or monitoring should be considered in
parallel with efforts to increase access to affordable and sustainable opioid substitution
therapy for dependent individuals.
Prescription monitoring programs (PMPs), which allow clinicians and pharmacists to
conduct real-time database queries in order to verify a patient’s medication dosing and
detect prescription alteration and “doctor shopping”, present one opportunity to approximate
levels of buprenorphine diversion and misuse. PMPs have the potential to alert public health
officials to potential epidemics of abuse and develop responses to engage illicit
buprenorphine users in formal treatment programs. Integrated monitoring, using novel
information sources like poison control centers, emergency departments, physicians,
community pharmacists, and medical examiners, can be used to identify emerging epidemics
of buprenorphine “doctor shopping,” diversion, and misuse, allowing public health officials
to direct resources toward targeted interventions [63, 96, 128, 129]. Although many existing
and developing systems can provide useful information at a state or regional level, more
localized surveillance could help to better identify areas with a high prevalence of
buprenorphine misuse [98]. In some locations with significant problems regarding the
misuse of prescription opioids, such as the United States, existing prescription monitoring
programs could incorporate efforts to monitor buprenorphine. In nations where prescription
drug diversion is not a major concern, infrastructure many not exist to monitor
buprenorphine diversion using PMPs. Additionally, in developing countries and resource-
limited settings, PMPs may not be a feasible way to monitor diversion. In any location with
a PMP, more active surveillance should also be directed to help physicians engage in safer
prescribing practices.
Monitoring of individuals who use buprenorphine, either through directly observed therapy
(DOT) or electronic monitoring that records the date and time of medication utilization,
could provide another alternative to ensuring compliance with buprenorphine treatment,
following a similar model to some antiretroviral adherence studies for HIV-positive
individuals in the U.S. In Finland, Tacke and colleagues recently reported on a pilot study
examining the feasibility and acceptability of electronic monitoring, using a device that
registers the time and date of tablet removal in a study sample of 12 buprenorphine patients.
The technology was well accepted and participants reported increased adherence to their
treatment plans and decreased diversion of buprenorphine [130]. The costs associated with
electronic monitoring devices may be unreasonable in resource limited settings, in locales
where patients must pay for their own treatment, or where insurance companies or
government agencies are hesitant to burden the extra cost.
Another approach to decrease the street demand for illicit buprenorphine could be to
increase availability of buprenorphine and buprenorphine/naloxone. Market economic
principles would suggest that, with greater availability, cost could decrease and access to
care and utilization of care could increase. This could potentially decrease the demand for
illicit buprenorphine.
Novel and Alternative Delivery Systems for Buprenorphine
Novel and alternative delivery systems could represent an innovative way to decrease
buprenorphine diversion without compromising access to affordable care. One example is
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alternate day dosing with sublingual buprenorphine, which was shown to be clinically
effective, feasible, and acceptable to patients over the past two decades [131–133]. In
situations where health care professionals directly observe patient dosing with
buprenorphine, alternate day dosing has the potential to allow patients to make fewer trips to
the dosing location and requires less contact time for health care professionals. Also, in
locations where diversion of buprenorphine take-home doses is an issue, alternate day
dosing at a medical facility could help to curtail diversion.
Clinical trials with Probuphine®, which utilizes sustained release technology in a hard-to-
extract subdermal implant, have shown steady blood levels of buprenorphine for at least six
months and little evidence of withdrawal [134]. Anecdotal evidence from trial participants
also indicates a preference for the subdermal product because of its lack of opioid effect and
absence of withdrawal symptoms [134]. Larger trials will be required before this product
can be utilized on a widespread basis.
Although many people who use buprenorphine therapeutically consume the medication
sublingually, it has been noted that IDUs who inject buprenorphine to alleviate withdrawal
symptoms may experience the same level of improvement as those who take it sublingually
[87]. In their 2008 manuscript, Aitken et al. suggest that an injectable form of buprenorphine
could be developed and prescribed by physicians for use in a community setting [87].
Further examination of the diversion potential, patient acceptability, clinical efficacy, and
physician opinion of an injectable form of buprenorphine would be necessary before such an
option could be offered to opioid-dependent IDUs.
Transdermal buprenorphine has also been studied, and could be utilized during acute
detoxification. Recent studies have shown that transdermal buprenorphine is safe, well-
tolerated, and clinically effective for heroin detoxification, suggesting that a 7-day
application of transdermal buprenorphine may be an effective mode of opioid detoxification
[135, 136].
The introduction of buprenorphine/naloxone combination product to areas that are currently
experiencing buprenorphine monoproduct diversion could reduce levels of diversion,
although this approach has not been validated by field experience [55]. The naloxone
component of buprenorphine/naloxone, which should precipitate withdrawal if injected by
opioid-dependent individuals [22–25], could result in lower levels of abuse and a lower
street value than buprenorphine monoproduct. In locations that do not currently allow the
use buprenorphine or buprenorphine/naloxone, initial introduction of buprenorphine/
naloxone may result in lower levels of abuse than what might be expected with the sole
introduction of buprenorphine monoproduct. In such areas, initial negative experiences with
the misuse of buprenorphine/naloxone may result in a low desirability and demand for illicit
buprenorphine and/or buprenorphine/naloxone.
Additionally, Reckitt-Benckiser, the manufacturer of brand name Suboxone® and Subutex®,
recently received approval to market Suboxone® film in the United States [137]. New
research examining buprenorphine diversion should consider the abuse potential of this form
of buprenorphine.
AREAS FOR FURTHER RESEARCH
Research is still needed to understand the motivating factors for the diversion, abuse, and
non-medically supervised use of buprenorphine, particularly in a context that is consistent
with the medication’s therapeutic purpose. Novel, longitudinal research is also needed to
understand the long-term implications of illicit buprenorphine use, including but not limited
to its effects on HIV-risk behavior and treatment seeking behavior for opioid dependence.
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Future clinical investigations could also examine the feasibility and efficacy of
intermittently prescribed buprenorphine for individuals who are interested in abstaining
from illicit opioid use but who are unwilling or unable to enter formal treatment. More
clinical research is needed to understand the efficacy, capabilities, and safety and diversion
concerns of novel forms of buprenorphine, including subdermal and transdermal patches and
implants and Suboxone film.
Also, more data are needed to understand the involvement of buprenorphine in overdose
events (particularly when used concomitantly with other substances), to assess other adverse
consequences, and to describe specifics as to why individuals inject buprenorphine,
including the role of injection buprenorphine in the drug use profiles of polydrug users.
Complications arising from injection buprenorphine use should be further investigated to
determine whether complications are unique to buprenorphine, a result of poly-drug use, or
are simply complications that can be expected of any injection drug use.
Countries that limit the number of patients per provider, such as the United States, should
critically examine these limits and assess their influence on provider availability and clinical
efficacy—expanding the number of patients allowed under these limits or removing them
entirely may provide enhanced access to buprenorphine treatment.
Additionally, countries currently offering directly observed therapy (DOT) buprenorphine
could examine the possibility of a transition to buprenorphine/naloxone, which may allow
for expanded access, take-home dosing, and/or a lower level of abuse potential. Finally,
future research could also examine the potential impact of over-the-counter sale of
buprenorphine or buprenorphine/naloxone, especially in locations where access to
prescribers is limited. More quantitative, qualitative, and ethnographic research and data are
needed on an international level to understand all of these issues.
CONCLUSIONS
Opioid abuse and dependency exert an important and pressing social, economic, and
biomedical toll throughout the world. Opioid substitution therapy has been proven to reduce
illicit opioid use, lower rates of arrest and recidivism, decrease rates of disease transmission,
and increase treatment compliance for co-occurring morbidities [15, 138–140].
Buprenorphine (Subutex® or generic) and buprenorphine/naloxone (Suboxone®) are
clinically safe and effective for the treatment of opioid dependency [13, 25, 36, 94, 138,
141]. Buprenorphine’s safety profile, ceiling effect at high doses, ability to be coformulated
with naloxone to limit injection abuse, and lower abuse potential compared to full opioid
agonists make it a suitable medication for office-based treatment of opioid dependency.
Wherever there is access to any medication with abuse potential, diversion is likely to
follow, making it unsurprising that buprenorphine diversion has been documented. In the
face of documented diversion, it is important to remember that buprenorphine is a clinically
effective and safe medication for the treatment of opioid dependence, with considerably
lower risk potential than other opioids.
Ultimately, introduction of buprenorphine to over 40 countries throughout the world has
increased access to an essential medication and helped hundreds of thousands of individuals
regain stability in their lives and avert negative health consequences associated with opioid
abuse and injection. These benefits—whether achieved through access to a legitimate
prescription or through the therapeutic use of diverted buprenorphine on the street—should
be considered, such that any attempt to limit the diversion and illicit use of buprenorphine
does not result in a concomitant decrease in the accessibility of this potentially life saving
medicine. Extensive efforts should be made to ensure adequate accessibility to affordable
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buprenorphine programs as an option for all individuals with opioid dependence and to
engage individuals who are currently self-treating opioid dependence with diverted
buprenorphine in formal treatment programs with proper medical and psychosocial support.
DEFINITIONS
In this document, the term “non-medically supervised use” refers to use that approximates
reasonable clinical use (sublingual administration). In contrast, the terms “misuse” and
“abuse” refer to the use of buprenorphine, either alone or in combination with other drugs, to
attain euphoria or “get high,” and also refer to instances of buprenorphine use in a dangerous
manner (for example, by intravenous administration). “Diversion” refers to the act of
redirecting buprenorphine or buprenorphine/naloxone from legitimate sources to illegitimate
or illegal ones. The term “buprenorphine” refers to the buprenorphine mono-product
(Subutex®), whereas “buprenorphine/naloxone” refers to the coformulated product
(Suboxone®). Suboxone® is coformulated in a 4:1 ratio of buprenorphine to naloxone, and is
available in 2mg/0.5mg and 8mg/2mg doses. Subutex® is generally available in 0.4mg, 2mg,
and 8mg doses.
Although buprenorphine diversion, abuse, misuse, and non-medically supervised use have
been examined in the current literature, manuscripts on this topic rarely explicitly define
these terms.
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Buprenorphine and buprenorphine/naloxone are clinically effective medications for
analgesic use and the treatment of opioid dependence. Diversion of buprenorphine and
buprenorphine is occurring throughout the world. The reasons for the diversion of these
medications are not entirely understood, but include utilization for euphoric effects and
self-treatment of opioid dependence. Ultimately, buprenorphine and buprenorphine/
naloxone are exciting, relatively new medications for the treatment of opioid dependence,
and efforts to control diversion should be considered in concert with efforts to increase
access to buprenorphine treatment for individuals with opioid dependence.
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Further research is needed to gain a better understanding of the motivations for and
effects of buprenorphine and buprenorphine/naloxone diversion, misuse, and non-
medically supervised use. The medical risks and benefits of illicit buprenorphine use
remain unclear. The implications of buprenorphine’s concomitant use with other drugs
(licit or illicit) and the subsequent risk of overdose should be examined in further detail.
Finally, new research is needed to examine the efficacy of existing diversion control
measures and to understand the potential impact of new formulations of buprenorphine
on diversion.
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